The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Drugs and Gene Delivery Systems Market Report By Route of Administration (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Vector, Viral, Non-viral), By Method (In Situ, Ex Vivo) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028
ID:VMR11214683
April 2021
Report Formats: Electronic (PDF), MS EXCEL
Global Drug and Gene Delivery Systems Market Overview
The key driver impacting the drug and gene delivery systems market is the growing demand for advanced drugs due to the increasing incidence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. For instance, The National Center for Biotechnology Information (NCBI) report presents that almost one in three adults suffers from multiple chronic conditions (MCCs). The WHO report shows that chronic disease accounts for 60% of the worldwide disease burden in 2020. Globally cancer is responsible for the second most leading cause of death, and it accounted for 9.6 million deaths in 2018. Similarly, diabetes is also one of the most prevalent diseases globally. As per the International Diabetic Federation (IDF), In 2019, over 463 million adults (20-79 years) were living with diabetes, and it is likely to reach 700 million by 2045. drug and gene delivery systems techniques are widely used to research and develop medicines, vaccines, antibiotics, and therapeutics used for treating such diseases. The escalating incidence of diseases such as diabetes and cancer has created a need for extensive research and enhancing drug discovery operations and research in the fields of biopharmaceuticals and biotechnology. Moreover, the growth in R&D investments with high demand for self-administration and home health care devices contributes to the drug and gene delivery systems market growth in the coming years.
The several advancements made in drug and gene delivery systems are estimated to augment drug and gene delivery systems needs in the forecast period. For example, technological advances such as Prodrug formulation particle engineering & particulate systems, nanoparticle technology, liposomes & hydrogels, and three-dimensional printing (3DP) to attain the sustained and controlled release of drugs. However, the high cost involved in the treatment may hamper the market in the long run. Also, the rise in drug recalls negatively impacts the market. The current industry trends, such as the rising investment by the market players to develop innovative drug delivery systems and high focus on R&D of gene delivery systems, are expected to offer new market opportunities for the key players.
The drug and gene delivery systems market is vast, with many local and global players. The drug and gene delivery systems market is extensive, with many international and regional players. The key market leaders follow several strategies to improve their market statuses, such as extending product portfolio, amalgamation, contracts, acquisitions, product upgrades to enlarge their market share across the globe. For instance, in February 2018, Becton, Dickinson, and Company had launched PAXgene. It is a circulating cell-free DNA blood collection tube for the application of pre-natal cancer testing. The important players studied in the report are Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono, Voyager Therapeutics Inc., Spark Therapeutics Inc. , Sangamo Therapeutics Inc, Others.
In this research report, the drug and gene delivery systems market is segmented by route of administration, vectors, methods, and region.
Analysis by Route of Administration
By route of administration, the report is categorized into oral, inhalation, transdermal, injectable, ocular, nasal, and topical. The oral segment dominates the route of the administration segment with over 25% share in 2020. It is due to the high potency and safety of biotechnology agents that are attracting biopharmaceutical companies to invest mainly in the research and development of these drugs. Moreover, pharmaceutical companies are focusing on reducing the amount of API per dose and increase the bioavailability at the site of action, thus contribute to the oral route of administration of drugs segment growth in the forecast period.
Analysis by Vector:
By vector, the report is categorized into viral and non-viral. Viral dominates the vector segment with over 90% share in 2020. It is because viral vectors allow complex procedures involved in various transfection procedures such as magnetofection, gene gun, hydrodynamic, and ultrasound at the high success rate of the gene transfer than its counterpart techniques. Moreover, more than 60% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection contributes to the increased demand for viral vectors segment in the forecast period.
Analysis by Method:
By the method, the report is categorized into in situ and ex vivo. In situ dominate the method segment with over 55% share in 2020. It is because most of the recently approved drugs act by in situ methods. Moreover, high focus on the in situ methods owing to their ease of performance contributes to the increased market demand in the forecast period.
Analysis by Region:
In the regional outlook of the global drug and gene delivery systems market, the North America region dominates globally with a 30% market share in the forecast period. It is due to the rising prevalence of chronic diseases in the area, technological advancement, and the domicile presence of significant players in the region. Moreover, the existence of well-established nanotechnology, biotechnology, and pharmaceutical industry, with massive awareness concerning advanced technologies for the treatment of chronic and genetic disease among the population of the U.S. and Canada, contribute to market growth across North America.
Market Segmentation covered in the Report:
By Route of Administration
The key driver impacting the drug and gene delivery systems market is the growing demand for advanced drugs due to the increasing incidence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. For instance, The National Center for Biotechnology Information (NCBI) report presents that almost one in three adults suffers from multiple chronic conditions (MCCs). The WHO report shows that chronic disease accounts for 60% of the worldwide disease burden in 2020. Globally cancer is responsible for the second most leading cause of death, and it accounted for 9.6 million deaths in 2018. Similarly, diabetes is also one of the most prevalent diseases globally. As per the International Diabetic Federation (IDF), In 2019, over 463 million adults (20-79 years) were living with diabetes, and it is likely to reach 700 million by 2045. drug and gene delivery systems techniques are widely used to research and develop medicines, vaccines, antibiotics, and therapeutics used for treating such diseases. The escalating incidence of diseases such as diabetes and cancer has created a need for extensive research and enhancing drug discovery operations and research in the fields of biopharmaceuticals and biotechnology. Moreover, the growth in R&D investments with high demand for self-administration and home health care devices contributes to the drug and gene delivery systems market growth in the coming years.
According to Value Market Research, the global drug and gene delivery systems market size was valued at around USD 1,810.44 million in 2021 and is estimated to grow at a CAGR of about 26.33% during the forecast period 2022 to 2028.
The several advancements made in drug and gene delivery systems are estimated to augment drug and gene delivery systems needs in the forecast period. For example, technological advances such as Prodrug formulation particle engineering & particulate systems, nanoparticle technology, liposomes & hydrogels, and three-dimensional printing (3DP) to attain the sustained and controlled release of drugs. However, the high cost involved in the treatment may hamper the market in the long run. Also, the rise in drug recalls negatively impacts the market. The current industry trends, such as the rising investment by the market players to develop innovative drug delivery systems and high focus on R&D of gene delivery systems, are expected to offer new market opportunities for the key players.
The drug and gene delivery systems market is vast, with many local and global players. The drug and gene delivery systems market is extensive, with many international and regional players. The key market leaders follow several strategies to improve their market statuses, such as extending product portfolio, amalgamation, contracts, acquisitions, product upgrades to enlarge their market share across the globe. For instance, in February 2018, Becton, Dickinson, and Company had launched PAXgene. It is a circulating cell-free DNA blood collection tube for the application of pre-natal cancer testing. The important players studied in the report are Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono, Voyager Therapeutics Inc., Spark Therapeutics Inc. , Sangamo Therapeutics Inc, Others.
In this research report, the drug and gene delivery systems market is segmented by route of administration, vectors, methods, and region.
Analysis by Route of Administration
By route of administration, the report is categorized into oral, inhalation, transdermal, injectable, ocular, nasal, and topical. The oral segment dominates the route of the administration segment with over 25% share in 2020. It is due to the high potency and safety of biotechnology agents that are attracting biopharmaceutical companies to invest mainly in the research and development of these drugs. Moreover, pharmaceutical companies are focusing on reducing the amount of API per dose and increase the bioavailability at the site of action, thus contribute to the oral route of administration of drugs segment growth in the forecast period.
Analysis by Vector:
By vector, the report is categorized into viral and non-viral. Viral dominates the vector segment with over 90% share in 2020. It is because viral vectors allow complex procedures involved in various transfection procedures such as magnetofection, gene gun, hydrodynamic, and ultrasound at the high success rate of the gene transfer than its counterpart techniques. Moreover, more than 60% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection contributes to the increased demand for viral vectors segment in the forecast period.
Analysis by Method:
By the method, the report is categorized into in situ and ex vivo. In situ dominate the method segment with over 55% share in 2020. It is because most of the recently approved drugs act by in situ methods. Moreover, high focus on the in situ methods owing to their ease of performance contributes to the increased market demand in the forecast period.
Analysis by Region:
In the regional outlook of the global drug and gene delivery systems market, the North America region dominates globally with a 30% market share in the forecast period. It is due to the rising prevalence of chronic diseases in the area, technological advancement, and the domicile presence of significant players in the region. Moreover, the existence of well-established nanotechnology, biotechnology, and pharmaceutical industry, with massive awareness concerning advanced technologies for the treatment of chronic and genetic disease among the population of the U.S. and Canada, contribute to market growth across North America.
Market Segmentation covered in the Report:
By Route of Administration
- Oral
- Inhalation
- Transdermal
- Injectable
- Ocular
- Nasal
- Topical
- Viral
- Non-viral
- In Situ
- Ex Vivo
- Cancer
- Infectious Diseases
- Rheumatoid Arthritis
- Genetic Disorders
- Neurological Disorders
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . DRUGS AND GENE DELIVERY SYSTEMS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Route Of Administration
3.7.2 Market Attractiveness Analysis By Vector
3.7.3 Market Attractiveness Analysis By Method
3.7.4 Market Attractiveness Analysis By Delivery Area
3.7.5 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1 Overview by Route Of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Route Of Administration
6.4 Oral Historic and Forecast Sales by Regions
6.5 Inhalation Historic and Forecast Sales by Regions
6.6 Transdermal Historic and Forecast Sales by Regions
6.7 Injectable Historic and Forecast Sales by Regions
6.8 Ocular Historic and Forecast Sales by Regions
6.9 Nasal Historic and Forecast Sales by Regions
6.10. Topical Historic and Forecast Sales by Regions
7 . GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET ANALYSIS BY VECTOR
7.1 Overview by Vector
7.2 Historical and Forecast Data
7.3 Analysis by Vector
7.4 Viral Historic and Forecast Sales by Regions
7.5 Non-viral Historic and Forecast Sales by Regions
8 . GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET ANALYSIS BY METHOD
8.1 Overview by Method
8.2 Historical and Forecast Data
8.3 Analysis by Method
8.4 In Situ Historic and Forecast Sales by Regions
8.5 Ex Vivo Historic and Forecast Sales by Regions
9 . GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET ANALYSIS BY DELIVERY AREA
9.1 Overview by Delivery Area
9.2 Historical and Forecast Data
9.3 Analysis by Delivery Area
9.4 Cancer Historic and Forecast Sales by Regions
9.5 Infectious Diseases Historic and Forecast Sales by Regions
9.6 Rheumatoid Arthritis Historic and Forecast Sales by Regions
9.7 Genetic Disorders Historic and Forecast Sales by Regions
9.8 Neurological Disorders Historic and Forecast Sales by Regions
9.9 Others Historic and Forecast Sales by Regions
10 . GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET ANALYSIS BY GEOGRAPHY
10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
10.3.1. Overview, Historic and Forecast Sales Analysis
10.3.2. North America By Segment Sales Analysis
10.3.3. North America By Country Sales Analysis
10.3.4. United State Sales Analysis
10.3.5. Canada Sales Analysis
10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
10.4.1. Overview, Historic and Forecast Sales Analysis
10.4.2. Europe by Segment Sales Analysis
10.4.3. Europe by Country Sales Analysis
10.4.4. United Kingdom Sales Analysis
10.4.5. France Sales Analysis
10.4.6. Germany Sales Analysis
10.4.7. Italy Sales Analysis
10.4.8. Russia Sales Analysis
10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
10.5.1. Overview, Historic and Forecast Sales Analysis
10.5.2. Asia Pacific by Segment Sales Analysis
10.5.3. Asia Pacific by Country Sales Analysis
10.5.4. China Sales Analysis
10.5.5. India Sales Analysis
10.5.6. Japan Sales Analysis
10.5.7. South Korea Sales Analysis
10.5.8. Australia Sales Analysis
10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
10.6.1. Overview, Historic and Forecast Sales Analysis
10.6.2. Latin America by Segment Sales Analysis
10.6.3. Latin America by Country Sales Analysis
10.6.4. Brazil Sales Analysis
10.6.5. Argentina Sales Analysis
10.6.6. Peru Sales Analysis
10.6.7. Chile Sales Analysis
10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
10.7.1. Overview, Historic and Forecast Sales Analysis
10.7.2. Middle East & Africa by Segment Sales Analysis
10.7.3. Middle East & Africa by Country Sales Analysis
10.7.4. Saudi Arabia Sales Analysis
10.7.5. UAE Sales Analysis
10.7.6. Israel Sales Analysis
10.7.7. South Africa Sales Analysis
10.7.8. Rest Of Middle East And Africa Sales Analysis
11 . COMPETITIVE LANDSCAPE OF THE DRUGS AND GENE DELIVERY SYSTEMS COMPANIES
11.1. Drugs And Gene Delivery Systems Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments
12 . COMPANY PROFILES OF DRUGS AND GENE DELIVERY SYSTEMS INDUSTRY
12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Company Revenue
12.3.3. Products
12.3.4. Recent Developments
12.4. Amgen Inc.
12.4.1. Company Overview
12.4.2. Company Revenue
12.4.3. Products
12.4.4. Recent Developments
12.5. Oxford Biomedica PLC
12.5.1. Company Overview
12.5.2. Company Revenue
12.5.3. Products
12.5.4. Recent Developments
12.6. Sibiono
12.6.1. Company Overview
12.6.2. Company Revenue
12.6.3. Products
12.6.4. Recent Developments
12.7. Voyager Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Company Revenue
12.7.3. Products
12.7.4. Recent Developments
12.8. Spark Therapeutics Inc.
12.8.1. Company Overview
12.8.2. Company Revenue
12.8.3. Products
12.8.4. Recent Developments
12.9. Sangamo Therapeutics Inc
12.9.1. Company Overview
12.9.2. Company Revenue
12.9.3. Products
12.9.4. Recent Developments
12.10. Others
12.10.1. Company Overview
12.10.2. Company Revenue
12.10.3. Products
12.10.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Route Of Administration (USD MN)
- Oral Market Sales by Geography (USD MN)
- Inhalation Market Sales by Geography (USD MN)
- Transdermal Market Sales by Geography (USD MN)
- Injectable Market Sales by Geography (USD MN)
- Ocular Market Sales by Geography (USD MN)
- Nasal Market Sales by Geography (USD MN)
- Topical Market Sales by Geography (USD MN)
- Analysis Market by Vector (USD MN)
- Viral Market Sales by Geography (USD MN)
- Non-viral Market Sales by Geography (USD MN)
- Analysis by Method (USD MN)
- In Situ Market Sales by Geography (USD MN)
- Ex Vivo Market Sales by Geography (USD MN)
- Analysis by Delivery Area (USD MN)
- Cancer Market Sales by Geography (USD MN)
- Infectious Diseases Market Sales by Geography (USD MN)
- Rheumatoid Arthritis Market Sales by Geography (USD MN)
- Genetic Disorders Market Sales by Geography (USD MN)
- Neurological Disorders Market Sales by Geography (USD MN)
- Others Market Sales by Geography (USD MN)
- Global Drugs And Gene Delivery Systems Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Drugs And Gene Delivery Systems Report
- Market Research Process
- Market Research Methodology
- Global Drugs And Gene Delivery Systems Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Route Of Administration
- Market Attractiveness Analysis by Vector
- Market Attractiveness Analysis by Method
- Market Attractiveness Analysis by Delivery Area
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Route Of Administration (USD MN)
- Oral Market Sales by Geography (USD MN)
- Inhalation Market Sales by Geography (USD MN)
- Transdermal Market Sales by Geography (USD MN)
- Injectable Market Sales by Geography (USD MN)
- Ocular Market Sales by Geography (USD MN)
- Nasal Market Sales by Geography (USD MN)
- Topical Market Sales by Geography (USD MN)
- Global Market Analysis by Vector (USD MN)
- Viral Market Sales by Geography (USD MN)
- Non-viral Market Sales by Geography (USD MN)
- Global Market Analysis by Method (USD MN)
- In Situ Market Sales by Geography (USD MN)
- Ex Vivo Market Sales by Geography (USD MN)
- Global Market Analysis by DELIVERY Area (USD MN)
- Cancer Market Sales by Geography (USD MN)
- Infectious Diseases Market Sales by Geography (USD MN)
- Rheumatoid Arthritis Market Sales by Geography (USD MN)
- Genetic Disorders Market Sales by Geography (USD MN)
- Neurological Disorders Market Sales by Geography (USD MN)
- Others Market Sales by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Top Company Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Healthcare
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments